Lost my bet with Theory. I’ll be back after my 30 days.

Maybe it does. I said it’s not going into the .20s. What’s your point?

I don’t think we see the .20s again. .39 has been good support. I think we have the same around the .34/.35 range.

We may also get the results of the Keytruda combo trial as well. I think any explosive move in SP would have to come from a PR that doesn’t come from NWBO. For example, a PR from Merck saying it’s collaborating with NWBO will have a greater effect on the SP than approval or NICE reimbursement.

I believe we’ll be in the $2-$3 range at that point. We should hear news about the collaborations, direct restart and EDEN prior to approval. I believe we’ll be back over $1 by the time approval comes. If there is some deal that is also announced at the same time that was contingent on approval, we could see $5+

Sure. It’s almost like we don’t know you and LC are the same person

Oddly enough, based on the fictional persona you have created, it is you that cannot objectively evaluate the upside of this investment. It is clear that your emotions have gotten the best of you based on your alleged experience at Kings College.

Why don’t you just leave? You’re not invested and not short. Yet, you post here daily. Why? Do you have no life?

Are you clueless? Read what I said in my earlier posts. Go back to complaining about Advent. It’s too easy to make you look dumb on these topics.

Read 2.3 clown. Since doctors don’t prescribe off-label, maybe you can solve the mystery and find out who does? 🤣🤣🤣

https://www.gov.uk/government/publications/guidance-on-the-licensing-of-biosimilar-products/guidance-on-the-licensing-of-biosimilar-products

Why don’t you post some evidence of that so I can laugh at you…

Go read the MHRA’s guidance and the FDA’s draft guidance

So when they start making DC-vax using flaskworks instead of the artisan method, it’s a different product? The process is the product? Keep on trying clown.

Why don’t you source your quotes? You have a tendency to mislead. What I said is no trial is going to be necessary because each drug needs to get approved on its own. Once that drug is approved, it can be used for off-label use.

As to your off label reimbursement, many states have laws in place that state they must be approved for reimbursement for life threatening diseases. For example, see California H&S Code Section 1367.21.

Sounds like you realized how stupid your last post was and decided to backtrack. Good job clown.

Doctors don’t prescribe off-label? What are you even talking about? Do you know what off-label means? It literally means prescribing a drug for a condition that it wasn’t approved for. You need to take break moron. You’re losing it.

Even if what you are saying is true, “basically the same” means that any study done by UCLA carries over to DCvax-L

Are we supposed to take your word for it when Linda Liau herself said they are the same? You make yourself lose all credibility when you keep beating a dead horse.

It’s the one you agreed to moron. Why do I care about what you said previously? This was the bet clown

Hey clown. Look at post #693848. I said .39

Of course you would like the longs to worry. This won’t get to winter without an approval. That will be a terrible day for you.

If a defendant has information about another defendant, then that information likely would not be privileged. There are very few instances of privilege and the only ones that possibly could pertain to this case are attorney/client, attorney work product or possibly trade secret.

If I was defense counsel, absolutely not. The level of culpability of each defendant is different. Why would a less culpable defendant bind themself to such an agreement? There definitely is coordination and sharing of information between defendants but I do not believe such an agreement exists.

This isn’t a breach of contract case where the elements are clearly defined. This area of law is relatively new with very little case law to refer to. The fact that these cases are advancing to this point is actually a good sign. I believe they have articulated loss causation in the complaint to a point where the MTD will be denied.

If the motion to amend is granted then that’s a great sign. It means the judge see a path forward. It’s the same as NWBO’s case. The MTD was granted with leave to amend. The Judge gave them a path forward.

They filed a motion for leave to amend. The Phunware case is likely not over.

The scenario that comes to mind is if they partner with someone who requires some type of control on the board.

Then why wasn’t that clause included in their last agreement if that truly is the norm? And why was it important enough to be mentioned in the annual report if that is normal?

From my understanding, NEO is named executive officer. It seems as if the current officers were to lose control of the company, it would trigger some type of payout (if this clause was included in the contract). The way things currently are, I don’t see that happening. However, if a partner was to come in with substantial control, that may be a reason why the officers would want that type of language in their contracts.

I guess so. I do appreciate his insight. He did mention the approval validates the technology and opens doors for the company. I believe that to be true as well.

It may come from another Streeterville loan or may be straight dilution. At this point, it’s not major dilution. As the OS goes higher, dilution has a smaller effect. For example, 50 million shares diluted with 500 million OS has a much larger effect than at 1.3 billion OS. We should have a decision before the end of the year.

Something is going on behind the scenes that is larger than NICE reimbursement. The last annual report mentioned that future employment agreements may have payments triggered by a change of control or the termination of a NEO. LP mentioned increasing the management team, restarting direct, building up manufacturing and starting the pediatric trial. They didn’t sign the deal with Roswell to sit on the tech. All these things cost money that we know NWBO doesn’t have. The cherry on top is NICE approval, or lack thereof. The MAA approval is huge but it not because of NICE revenue. LP doesn’t plan to pay for all of this by diluting at .40 a share. I’m convinced there is going to a large influx of cash shortly after approval.

You haven’t won yet. We agreed at .39. That means .3900

Yea but .50 we get a break from this username for 30 days. You can continue using LC.

It wasn’t zero upfront. Learn to read.

“The terms of the Roswell license include standard provisions for an upfront license fee…”

Great, so we won’t see you for a month once it does.

Read a little more carefully. There is an upfront fee.

“The terms of the Roswell license include standard provisions for an upfront license fee”

There aren’t a large amount of suitors for this type of tech. NWBO is uniquely positioned because they already inlicensed previous work. The cost goes down when there aren’t a bunch of buyers. You confusing cost vs value.

“Taken together, the Company believes that the two portfolios comprise a whole that is greater than the sum of its parts and offer compelling synergies with the Company’s own portfolio.”

Still can’t answer my question? Just like your claim she makes 4x the salary of the average biotech CEO. You and LC can continue making your BS claims. Just remember to sign onto the right account when you’re making them.

You completely missed the question. I don’t need a history lesson. The application is submitted. What is she currently doing that is delaying the application from being processed?

How are they slow walking an application that has been submitted? I would love to hear that explanation.

That’s what you fail to understand. Profits and revenue come after approval. If this thing doesn’t get approval, this goes to zero. If it does, price appreciates by at least 5x from today’s prices. Advent, options and all that other crap you keep harping on don’t matter. There’s asymmetric reward to risk.